APA (7th ed.) Citation

Shah, M. A., Wainberg, Z. A., Catenacci, D. V. T., Hochster, H. S., Ford, J., Kunz, P., . . . Bottaro, D. P. (2022). Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. PLoS ONE, 17(10), 1. https://doi.org/10.1371/journal.pone.0276211

Chicago Style (17th ed.) Citation

Shah, Manish A., et al. "Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), CMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer." PLoS ONE 17, no. 10 (2022): 1. https://doi.org/10.1371/journal.pone.0276211.

MLA (9th ed.) Citation

Shah, Manish A., et al. "Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), CMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer." PLoS ONE, vol. 17, no. 10, 2022, p. 1, https://doi.org/10.1371/journal.pone.0276211.